Nilotinib
Resistant to Tyrosine Kinase Inhibitor Therapy
University Health Network, TorontoSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
181 Active assets in the Resistant to Tyrosine Kinase Inhibitor Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Catequentinib Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Irinotecan M.D. Anderson Cancer Center | Phase 2 | BB |
Durvalumab OHSU Knight Cancer Institute | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Catequentinib First Affiliated Hospital of Wannan Medical College | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →